Inhalation Digital Issue Now Available
 
photoNew at PharmSci360 2018
 
PharmSci360 2018 (previously the AAPS Annual Meeting and Exposition) will be held November 4-7, 2018 at the Walter E. Washington Convention Center in Washington, DC, US. As of September 3, the following companies, who have recently advertised in Inhalation, will be exhibiting new products or services during the conference. Content is provided by the companies listed. No product endorsement or preference is intended.
 
Catalent
 
At AAPS, Catalent will be showcasing its solutions for the development of inhalation and nasal drug products. Catalent leverages decades of experience in formulation, particle size engineering and manufacturing to accelerate and advance molecules and development programs across multiple dosage forms. Catalent's inhalation manufacturing operations have a track record of regulatory excellence and it manufactures MDIs, DPIs and nasal formulations for customers around the globe.
 
US: +1 888 SOLUTION
 
 
 
Hovione
 
Hovione offers development and compliant manufacture of innovative new drugs and niche generic active pharmaceutical ingredient (API) products. Hovione also supports highly potent compounds and offers proprietary product development and licensing opportunities for drug products. The company undertakes formulation development and clinical supply of final dosage forms to Phase II. With strong expertise in pulmonary delivery, Hovione offers APIs for inhalation, DPI devices, particle engineering and formulation development.
 
Portugal: +351 21 982 9000
 
 
 
Lonza
 
Strong bio-performance of your inhaled therapeutics is key to realizing optimal patient outcomes. Lonza supports you in optimizing performance, leveraging unique capabilities and expertise in product design and particle engineering. You gain access to a large array of specialized tools, including micronization, spray dry processing and nanocrystal technologies. Combined with formulation expertise for both small and large molecules, specialized DPI capsules, and finished product manufacturing capabilities to commercial scale, we bring your product from concept to market.
 
US: +1 800 706-8655
ROW: +44 1506 448080
 
 
 
MSP, a division of TSI
 
MSP, a division of TSI, offers one of the world's most comprehensive lines of qualification services for pharmaceutical inhaler testing systems. A leading supplier of DDU and PSD testing equipment, we offer a suite of equipment and services, addressing needs from basic to fully automated inhalation testing methods, and mensuration, calibration, IQ/OQ and consulting services. We are industry experts committed to helping our customers maintain the quality of their inhaler testing equipment, continually improving efficiency and productivity.
 
US: +1 651 287-8100
 
 
 
 
 
Qualicaps
 
Qualicaps®' history of innovation includes the first capsule specially formulated for inhalation applications, Quali-V®-I. These two-piece hypromellose capsules have low moisture content (4.5-6.5%) for improved stability with no brittleness, resulting in good puncturing and cutting characteristics for DPI applications. Quali-V-I capsules are less susceptible to static, so less powder clings to the capsule surface during inspiration. As an innovator of inhalation application capsules, Qualicaps has extensive experience in capsule formulation and research to help with your inhalation development needs.
 
US: +1 336 449-3926
 
 
 
 
 
Recipharm
 
Recipharm will be highlighting its expanded development and manufacturing capabilities for novel respiratory products at AAPS. The CDMO recently acquired Sanofi's Holmes Chapel, UK site, which specializes in the manufacture of metered dose inhalers and nasal sprays and complements the inhalation development expertise offered by Recipharm in Research Triangle Park, North Carolina. The CDMO has expertise in drug substance production through formulation and delivery device development, analytical testing and cGMP commercial-scale manufacturing.
 
Sweden: + 46 8 602 52 00
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S-Matrix
 
S-Matrix offer Fusion QbD® Software Platform–integrated modules for automated respiratory drug product R&D and QC testing; Fusion Product Development module (FPD)–QbD formulation and device R&D; and Fusion Inhaler Testing module (FIT)–formal product QC testing and reporting. The platform fully supports Part 11 Compliance and all USP and Ph.Eur. apparatuses, including FSI, FSA and DUSA; automates HPLC testing and data handling on your CDS; and meets all USP and Ph.Eur. PSD calculation and reporting requirements.
 
US: +1 707 441-0406
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhalation Magazine • www.inhalationmag.com
 
Copyright 2018, CSC Publishing Inc. All Rights Reserved • Privacy policy